EirGenix Advances Dual-Track Biosimilar and CDMO Strategy, Targeting HER2-Positive Breast Cancer and Global Supply Chain Opportunities
核心洞察
EirGenix (搜索) is pursuing a dual strategy combining biosimilar development with CDMO services, with a pipeline focused on HER2-positive breast cancer (搜索) including trastuzumab, pertuzumab, and next-generation ADC biosimilars.
Global regulatory agencies are streamlining biosimilar approval pathways, reducing reliance on large Phase III trials and favoring in vitro comparability and pharmacokinetic bioequivalence data.
The company's Hsinchu facility capacity is secured through 2030, with expansion plans including potential acquisitions in the U.S. and land reserved in Kaohsiung's Qiaotou Science Park.
At BIO 2026, Taiwan-based EirGenix (搜索) presented its comprehensive HER2-positive breast cancer (搜索) biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform, actively pursuing U.S. market opportunities through business matchmaking and global partnership discussions.
The company's dual-track approach combines targeted biosimilar development with a flexible CDMO model, capturing high-potential oncology opportunities while helping partners accelerate global commercialization. As Dr. Portia Lin, Senior Vice President and Chief Business Officer at EirGenix (搜索), explained in an interview with GeneOnline, the two businesses are highly complementary: "CDMO services provide stable cash flow and help maximize facility utilization. That supports our long-term biosimilar strategy."
HER2-Positive Breast Cancer: A Core Strategic Focus
According to the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer in 2022, making it the second most commonly diagnosed cancer worldwide. Market research from Grand View Research projects that the global breast cancer drug market will expand from USD 36.6 billion in 2024 to USD 69.7 billion by 2033, representing a compound annual growth rate of 7.1%.
HER2-positive breast cancer (搜索) accounts for approximately 15% to 20% of all breast cancer cases. Historically associated with aggressive tumor biology and poor prognosis, this subtype was transformed by the introduction of trastuzumab, which validated HER2 (搜索) as a therapeutic target. Since then, innovation has accelerated with dual-target regimens, subcutaneous formulations, and antibody-drug conjugate (ADC)-based approaches reshaping the competitive landscape.
EirGenix (搜索)'s biosimilar portfolio spans multiple modalities targeting HER2-positive breast cancer (搜索), including trastuzumab and pertuzumab, as well as subcutaneous combination formulations designed to improve treatment convenience and administration efficiency. The company is also advancing development efforts in next-generation ADC biosimilars.
Beyond single-agent development, EirGenix (搜索) is exploring combination therapy strategies to address mechanisms of resistance in oncology treatment. These include potential co-development approaches involving ADC biosimilars alongside immune checkpoint inhibitors such as atezolizumab, as well as other targeted therapies including daratumumab.
A Favorable Regulatory and Market Environment
The global biopharmaceutical industry is entering a major patent cliff. Approximately $300 billion of biologics are expected to lose patent protection over the next decade, creating significant opportunities for biosimilar developers. Notably, while 118 biologics are set to lose exclusivity by 2034, 106 of them currently have no biosimilars in development.
At the same time, global regulatory frameworks are becoming increasingly harmonized. Agencies such as the U.S. Food and Drug Administration and the European Medicines Agency are aligning expectations for biosimilar approval pathways. Development requirements are increasingly focused on in vitro comparability and pharmacokinetic bioequivalence data, reflecting a more streamlined regulatory approach that reduces reliance on large-scale Phase III clinical trials, ultimately shortening development timelines while lowering costs and clinical risk.
Dr. Lin noted that this regulatory evolution could attract more traditional generic drug manufacturers into the biosimilar market. "Many of these companies lack biologics development and CMC expertise, creating additional opportunities for experienced CDMOs," she said.
CDMO Services as a Strategic Pillar
Beyond biosimilars, CDMO services represent the second core pillar of EirGenix (搜索)'s business strategy. Global supply chain restructuring, the rapid rise of biotech startups, and increasing demand for biologics are reshaping outsourcing models across the pharmaceutical industry.
EirGenix (搜索) provides integrated CDMO services across the full product lifecycle, spanning cell line engineering, process and analytical development, technology transfer, and GMP manufacturing. Its service scope covers monoclonal antibodies, bispecific antibodies, and other complex biologics.
The company's Hsinchu facility currently operates two manufacturing lines, each equipped with six 2,000-liter bioreactors. Based on current projections, available capacity should be sufficient through 2030. However, with several internally developed biosimilars expected to approach commercialization around that timeframe, EirGenix (搜索) has already begun planning its next growth phase, reserving land in Kaohsiung's Qiaotou Science Park for potential future expansion and evaluating acquisition opportunities involving existing biologics manufacturing facilities in the United States.
Dr. Lin emphasized that modern CDMO relationships extend beyond traditional contract manufacturing. "Future CDMO relationships will not be limited to simple manufacturing transactions," she said. EirGenix (搜索) already leverages its regulatory expertise to support customer submissions and helps clients identify commercialization opportunities and potential market partners, including cross-border licensing facilitation.
Navigating Geopolitical Uncertainty
Geopolitical tensions have become a defining challenge for global pharmaceutical manufacturing. The proposed U.S. Biosecure Act and broader policy initiatives supporting domestic production have prompted pharmaceutical companies to reassess sourcing strategies.
"Some customers continue to express concerns about geopolitical risks across Asia, even though Taiwan is not subject to the same restrictions facing China," Dr. Lin noted. In response, EirGenix (搜索) has adopted an early-engagement strategy in the United States, primarily collaborating with startups, academic institutions, and hospital-based programs during early development stages.
Japan represents another key market. According to Dr. Lin, Japan lacks sufficient large-scale commercial biologics drug substance manufacturing capacity, and many Japanese pharmaceutical companies prefer licensing partnerships rather than investing heavily in new manufacturing infrastructure. EirGenix (搜索) currently supplies two commercialized customer products to Japan and expects two additional customer products to pursue regulatory approvals across multiple countries beginning in 2027.
Internal Safeguards and Operational Structure
To address potential conflicts of interest between its biosimilar development and CDMO operations, EirGenix (搜索) maintains strict internal safeguards. "We simply do not accept projects that overlap with our own proprietary biosimilar programs," Dr. Lin stated. The company operates its BioPharma and BioManufacturing divisions as independent business units, with project management, regulatory affairs, manufacturing operations, and capacity planning all managed separately.
Dr. Lin identified talent as the industry's greatest long-term challenge, noting that the semiconductor and AI industries exert tremendous attraction for talent. "That pressure affects every other sector, including biotechnology," she said. EirGenix (搜索) currently manages four to five Process Performance Qualification projects annually as multiple programs advance toward commercialization, providing valuable opportunities for teams to accumulate real-world experience.